Myelofibrosis Clinical Trials

298 clinical trials for Myelofibrosis across international registries, including 68 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia — RECRUITING · PHASE1
• A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib — RECRUITING · PHASE3
• A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis — RECRUITING · PHASE1
• Quantitative MRI for Myelofibrosis — RECRUITING
• A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms — RECRUITING · PHASE1
• A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant — RECRUITING · PHASE1
• A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis — RECRUITING · PHASE1
• A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis — RECRUITING · PHASE1
• A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis — RECRUITING · PHASE2
• Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) — RECRUITING · PHASE1
• Clinical Epidemiology in Contemporary Patients With Myelofibrosis. — RECRUITING
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors — RECRUITING · PHASE1
• Research Platform Myelofibrosis and Anemia — RECRUITING
• AlloHCT With PegINFa for Myelofibrosis — RECRUITING · PHASE1
• Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant — RECRUITING · PHASE1
• Therapeutic RSK1 Targeting in Myelofibrosis — RECRUITING · PHASE1
• Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) — RECRUITING · PHASE2
• Methods of T Cell Depletion Trial (MoTD) — RECRUITING · PHASE2
• Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. — RECRUITING · PHASE1
• Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow — RECRUITING · PHASE1
• Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis — RECRUITING · NA
• To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects — RECRUITING · PHASE1
• A Telehealth Advance Care Planning Intervention — RECRUITING · NA
• A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) — RECRUITING · PHASE3
• Momelotinib During and After HCT in Myelofibrosis — RECRUITING · PHASE1
• Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms — RECRUITING · PHASE2
• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation — RECRUITING · PHASE2
• High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly — RECRUITING · PHASE2
• An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms — RECRUITING · PHASE1
• CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant — RECRUITING · PHASE2
• Clonal Architecture of ASXL1-mutated Myelofibrosis — RECRUITING · NA
• A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor — RECRUITING · PHASE1
• A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept — RECRUITING · NA
• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia — RECRUITING · PHASE2
• A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis — RECRUITING · PHASE2
• 18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study. — RECRUITING
• Clinical Validation Study: Evaluation of TSO Comp (DRAGEN) Assay for Detection of Tumor Protein 53 (TP53) Status in Peripheral Blood From Patients With Myelofibrosis to Support Study KRT-232-115 — RECRUITING
• MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) — RECRUITING
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis — RECRUITING · PHASE1
• MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial — RECRUITING · PHASE2
• A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) — RECRUITING · PHASE1
• Two Step Haplo With Radiation Conditioning — RECRUITING · PHASE2
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry — RECRUITING
• Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies — RECRUITING · PHASE1
• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — RECRUITING · PHASE3
• RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ADD-ON STUDY EVALUATING THE SAFETY AND EFFICACY OF NAVTEMADLIN PLUS RUXOLITINIB VS PLACEBO PLUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS WHO HAVE A SUBOPTIMAL RESPONSE TO RUXOLITINIB — RECRUITING · PHASE3
• A Study of GLB-001 in Patients With Myeloid Malignancies — RECRUITING · PHASE1

Refine this search